论文部分内容阅读
目的观察布地奈德治疗小儿咳嗽变异性哮喘(CVA)的临床疗效。方法 61例CVA患者分为治疗组和对照组,对照组用孟鲁司特治疗,治疗组布地纳德联合孟鲁司特治疗,观察临床疗效、复发率和不良反应。结果两组临床疗效明显,治疗组症状改善时间明显低于对照组(P<0.05),治疗后血EOS比例下降比例以及PEF升高值明显优于对照组(P<0.05)。治疗后后3个月复发率明显低于对照组,不良反应小。结论布地奈德联合孟鲁司特治疗CVA,疗效确切、复发率低、不良反应少,值得临床推广。
Objective To observe the clinical efficacy of budesonide in the treatment of children with cough variant asthma (CVA). Methods Sixty-one patients with CVA were divided into treatment group and control group. The control group was treated with montelukast and the treatment group Budenad combined with montelukast. The clinical efficacy, recurrence rate and adverse reactions were observed. Results The clinical curative effect was obvious in both groups, and the symptom improvement time in the treatment group was significantly lower than that in the control group (P <0.05). After treatment, the decrease ratio of EOS and the increase of PEF were obviously better than the control group (P <0.05). Three months after treatment, the recurrence rate was significantly lower than the control group, adverse reactions. Conclusions Budesonide combined with montelukast in the treatment of CVA has definite curative effect, low recurrence rate and few adverse reactions, which deserves clinical promotion.